Published in Blood on May 05, 2005
Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell (2010) 5.28
Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med (2006) 1.63
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood (2010) 1.55
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself (2010) 1.45
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med (2007) 1.30
Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood (2005) 1.22
Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13
Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol (2012) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Targeting human dendritic cell subsets for improved vaccines. Semin Immunol (2011) 1.09
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J Clin Invest (2007) 1.06
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol (2010) 1.02
HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A (2009) 0.98
Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J Immunol (2012) 0.97
Cross-presentation: how to get there - or how to get the ER. Front Immunol (2012) 0.95
Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv (2013) 0.94
Intracellular events regulating cross-presentation. Front Immunol (2012) 0.93
Targeting Dendritic Cells in vivo for Cancer Therapy. Front Immunol (2012) 0.93
Non-carbohydrate inhibitors of the lectin DC-SIGN. J Am Chem Soc (2007) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology (2013) 0.89
Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccin (2011) 0.89
Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. MBio (2010) 0.88
Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J Immunol (2008) 0.87
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med (2007) 0.86
Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol (2011) 0.85
DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol (2013) 0.85
Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells. EBioMedicine (2016) 0.84
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. Oncoimmunology (2014) 0.84
Human Milk Blocks DC-SIGN-Pathogen Interaction via MUC1. Front Immunol (2015) 0.83
Engineering better immunotherapies via RNA interference. Hum Vaccin Immunother (2014) 0.82
Guiding principles in the design of molecular bioconjugates for vaccine applications. Bioconjug Chem (2015) 0.81
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. J Am Soc Nephrol (2015) 0.81
Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: a novel tool for specific immunotherapy. J Control Release (2012) 0.81
Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response. Immunology (2007) 0.80
Dendritic cells and vaccine design for sexually-transmitted diseases. Microb Pathog (2012) 0.80
Exploiting fungal cell wall components in vaccines. Semin Immunopathol (2014) 0.80
Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery. Curr Opin Chem Eng (2015) 0.80
Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE). PLoS One (2009) 0.78
In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses. J Invest Dermatol (2015) 0.78
AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN. Antimicrob Agents Chemother (2007) 0.78
Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition. JCI Insight (2016) 0.78
The Consequences of Multiple Simultaneous C-Type Lectin-Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN. Front Immunol (2015) 0.78
Human blood dendritic cell subsets exhibit discriminative pattern recognition receptor profiles. Immunology (2014) 0.78
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines (Basel) (2016) 0.77
Transcriptional fingerprints of antigen-presenting cell subsets in the human vaginal mucosa and skin reflect tissue-specific immune microenvironments. Genome Med (2014) 0.76
MGL Receptor and Immunity: When the Ligand Can Make the Difference. J Immunol Res (2015) 0.76
Immunotherapy: Cancer vaccine triggers antiviral-type defences. Nature (2016) 0.76
Loss of sialic acid binding domain redirects protein σ1 to enhance M cell-directed vaccination. PLoS One (2012) 0.76
C-type Lectin Receptors for Tumor Eradication: Future Directions. Cancers (Basel) (2011) 0.76
Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance. Hum Vaccin Immunother (2016) 0.75
Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine. Cell Mol Immunol (2014) 0.75
Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes. J Biomed Biotechnol (2010) 0.75
Dendritic cell targeted vaccines: Recent progresses and challenges. Hum Vaccin Immunother (2016) 0.75
Dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron (2017) 0.75
Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination. Rev Diabet Stud (2012) 0.75
Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants. Sci Rep (2016) 0.75
Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest (2006) 4.45
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol (2002) 3.44
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.01
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med (2004) 2.80
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol (2008) 2.62
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (2008) 2.60
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology (2013) 2.17
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol (2010) 2.13
Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol (2008) 2.11
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res (2004) 2.06
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol (2005) 2.02
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain (2010) 1.90
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol (2005) 1.89
Myosin II and mechanotransduction: a balancing act. Trends Cell Biol (2007) 1.85
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood (2011) 1.83
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol (2006) 1.77
How C-type lectins detect pathogens. Cell Microbiol (2005) 1.77
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer (2012) 1.73
Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem (2002) 1.71
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther (2010) 1.67
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 1.60
Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A (2009) 1.60
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol (2003) 1.53
Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem (2008) 1.50
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49